

1 Genetic Insights into Cardiac Conduction Disorders from 2 Genome-Wide Association Studies

3 **Running title:** GWAS Uncovers Genetic Links to Cardiac Conduction Disorders

4

5 Bingxun Li, PhD^{1,2*}, Hongxuan Xu, PhD^{1,2*} and Lin Wu, MD^{1,2,3#}

6 ¹Department of Cardiology, Peking University First Hospital, Beijing, China.

7 ²State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University

8 ³Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute of
9 Cardiovascular Research, Southwest Medical University, Luzhou, China.

10 #Corresponding author: Lin Wu; E-mail: wuepgroup@126.com; address: NO.8
11 Xishiku Street, Department of Cardiology, Peking University First Hospital, Beijing,
12 China.

13 *These authors contributed equally to this study.

14

15 Number of total words: 4,465

16 Number of words in the abstract: 197

17 Number of references: 40

18

19 **ABSTRACT**

20 **BACKGROUND:** Substantial data support a heritable basis for cardiac conduction
21 disorders (CCDs), but the genetic determinants and molecular mechanisms of these
22 arrhythmias are poorly understood, therefore, we sought to identify genetic loci
23 associated with CCDs. **METHODS:** We performed meta-analyses of genome-wide
24 association studies to identify genetic loci for atrioventricular block (AVB), left
25 bundle branch block (LBBB), and right bundle branch block (RBBB) from public
26 data from the UK Biobank and FinnGen consortium. We assessed evidence
27 supporting the potential causal effects of candidate genes by analyzing relations
28 between associated variants and cardiac gene expression, performing
29 transcriptome-wide analyses, and ECG-wide phenome-wide associations for each
30 indexed SNP. **RESULTS:** Analysis comprised over 700,000 individuals for each trait.
31 We identified 10, 4 and 0 significant loci for AVB (*PLEKHA3*, *TTN*, *FNDC3B*,
32 *SEN2*, *SCN10A*, *RRH*, *PPARGC1A*, *PKD2L2*, *NKX2-5* and *TBX20*), LBBB
33 (*PPARGC1A*, *HAND1*, *TBX5*, and *ADAMTS5*) and RBBB, respectively.
34 Transcriptome-wide association analysis supported an association between reduced
35 predicted cardiac expression of *SCN10A* and AVB. Phenome-wide associations
36 identified traits with both cardiovascular and non- cardiovascular traits with indexed
37 SNPs. **CONCLUSIONS:** Our analysis highlight gene regions associated with channel
38 function, cardiac development, sarcomere function and energy modulation as
39 important potential effectors of CCDs susceptibility.

40 **Key words:** Genome-Wide Association Studies, cardiac conduction disorders,

41 meta-analysis

42

43 The cardiac conduction system is crucial for propagating electrical signals that
44 coordinate cardiac contractions to maintain effective blood circulation. Disturbances
45 in this system, termed cardiac conduction disorders (CCDs), can disrupt heart
46 depolarization and even result in bradycardia. Common manifestations of CCDs
47 include sick sinus syndrome (SSS), atrioventricular block (AVB), left bundle branch
48 block (LBBB), and right bundle branch block (RBBB). While significant progress has
49 been made in understanding the molecular mechanisms driving CCDs, current
50 treatments for CCDs is limited and primarily rely on implantable devices such as
51 pacemakers¹. As a result, further research is needed to enhance our understanding and
52 facilitate the development of pharmacological or genetic therapies².

53 Although some CCDs can arise secondary to conditions such as ischemia, toxins,
54 or infections¹, genetic factors also play a significant role in their development, with
55 studies indicating that CCDs and risk for pacemaker insertion cluster within
56 families^{3,4}. Some researchers also suggested to include genetic testing as part of the
57 diagnostic workup in AVB patients⁵. In 2021, Thorolfsdottir et al. conducted a
58 genome-wide association study (GWAS) that identified several novel genetic variants
59 associated with SSS, underscoring a strong genetic basis⁶. However, GWAS studies
60 on other major CCDs such as AVB, LBBB, or RBBB, are not yet fully explored. To
61 address this gap, we performed a meta-analysis of GWAS data on AVB, LBBB, and
62 RBBB to gain further insight into the pathogenesis of these disorders.

63 **Methods**

64 **Study samples and meta-analysis**

65 The study was reported according to STrengthening the REporting of Genetic
66 Association Studies (STREGA) guideline⁷. **Figure 1** depicts the study design. We
67 included individuals with the phenotypes of interest from UK Biobank⁸ and the
68 FinnGen consortium release 11⁹. Details of each cohort as well as download link of
69 GWAS summary statistics are provided in Supplemental Table 1. Because those
70 GWAS data are from two independent cohorts, there was no risk sample overlap. We
71 then conducted meta-analysis of included GWAS analyses using a fixed-effects
72 inverse variance weighted approach implemented in METAL¹⁰, utilizing the default
73 method that incorporates p-values and the direction of effect, weighted by sample size.
74 To address potential population stratification bias, we applied genomic control to all
75 input files. SNPs with allele frequency < 0.5% were excluded from our analysis¹¹.

76 Because the output file of METAL doesn't include BETA and SE (standard error),
77 which are essential for further analysis, we calculated the above parameters from the
78 following formulations¹²:

$$79 \quad SE = \sqrt{\frac{1}{2 \times EAF \times (1 - EAF) \times (N + Z^2)}}$$
$$80 \quad BETA = Z \times SE$$

81 where EAF is effect allele frequency, N is sample size, and Z is Z score.

82 **Identification of independent locus and novel genes**

83 We used the 1000 Genomes Project phase 3 European (EUR) sample for linkage

84 disequilibrium (LD) estimation via the plinkbinr (version 0.0.0.9) and ieugwasr
85 (version 1.0.2) packages in R (version 4.1.1). Independent locus were defined using
86 a strict standard (clump window = 1Mb, $r^2 \leq 0.001$ and p-value $< 5 \times 10^{-8}$). Novel
87 locus were defined as variants more than 500 kb from previously reported ones. We
88 identified the gene closest to the indexed SNP according to Ensembl within a 500 KB
89 region. CADD (Combined Annotation Dependent Depletion) scaled score for each
90 SNP was looked up in the CADD v1.7 website (<https://cadd.gs.washington.edu/snv>)¹³.

91 **Transcriptome-wide association study**

92 We applied transcriptome-wide association study (TWAS) to identify significant
93 expression-trait associations using expression imputation from genetic data or
94 summary statistics with FUSION software¹⁴. This software trains predictive models of
95 the genetic component of a functional or molecular phenotype and predicts and tests
96 that component for association with disease using GWAS summary statistics.
97 FUSION software was used to generate SNP weight sets from BLUP, BSLMM,
98 LASSO, Elastic Net, and top SNPs utilizing genotype and expression data unless
99 BLUP/BSLMM was eliminated owing to sample size or convergence issues. Our goal
100 was to identify associations between the phenotypes of interest and a functional
101 phenotype measured only in reference data; for this analysis, we selected the GTEx
102 version 8 heart left ventricle data¹⁵. A false discovery rate (FDR) < 0.05 was
103 considered significant. In addition, we conducted colocalization analysis for results
104 with p-value < 0.05 using the coloc package (version 5.1.1)¹⁶. Colocalization was
105 assessed via posterior probability for hypothesis 4 (PP.H₄), with PP.H₄ $> 80\%$
106 indicating significant shared causal variants. We also conduct the joint/conditional
107 tests for further verification.

108 **LD score regression**

109 We used LD Score regression (LDSC)¹⁷ to estimate genetic correlations between
110 AVB, LBBB, and RBBB with 9 cardiovascular traits, including Brugada syndrome¹⁸,
111 heart failure (HF)¹⁹, coronary heart disease (CAD)²⁰, atrial fibrillation (AF)²¹, SSS⁶,
112 QRS duration (from Pan-UKBB GWAS), PR interval²², systolic blood pressure
113 (SBP)²³ and heart rate (HR)²⁴ utilizing the ldsc package (version 0.1.0) in R.
114 European LD scores were obtained from the 1000 Genomes Project Phase 3 data for
115 HapMap2 SNPs. A p-value below 0.0019 (0.05/9/3) was considered significant for
116 LDSC. Additionally, we also analyzed the genetic associations of each clumped SNP
117 against those risk factors.

118 **Phenome-wide Mendelian randomization**

119 To perform Phenome-wide Mendelian randomization (PheWAS) analysis, we
120 queried the GWAS atlas database (<https://atlas.ctglab.nl>)²⁵, which contains 4756
121 GWAS summary statistics for each indexed SNP. P-values $< 7.51 \times 10^{-7}$
122 (0.05/4756/14) was considered as significant. For those PheWAS results fulfilled the
123 adjusted p-value, we also conducted colocalization analysis for further verification.

124 **ECG-wide association analyses.**

125 Clumped variants of LBBB and AVB GWAS data were looked up in ECGGenetics
126 (<http://www.ecgenetics.org>)²⁶ to explore their effect on R-R adjusted three-lead
127 exercise electrocardiogram (ECG) morphology. The GWAS for ECG morphology

128 consists of comprehensive deep phenotyping of 77,190 ECGs in the UK Biobank
129 across the complete cycle of cardiac conduction by plotting 500 association signals of
130 each datapoint as $-\log_{10}(\text{p-values})$ along the time axis of one heartbeat. This analysis
131 aims to assess the impact of clumped LBBB and AVB variants on ECG morphology,
132 leveraging extensive phenotyping data from the UK Biobank. By visualizing the
133 association signals as $-\log_{10}(\text{p-values})$, the study seeks to elucidate the relationship
134 between genetic variants and cardiac conduction throughout a complete heartbeat.

135 **Results**

136 **Meta-analysis results and gene annotation revealed novel genes for AVB and** 137 **LBBB**

138 We conducted meta-analyses of genome-wide association results for AVB,
139 LBBB, and RBBB using data from the UK Biobank and FinnGen consortium. After
140 quality control, we analyzed 19,629,603 SNPs for AVB, 19,630,647 SNPs for LBBB,
141 and 19,631,437 SNPs for RBBB, respectively. Manhattan plots for each trait are
142 shown in **Figure 2**, while quantile-quantile (QQ) plots and lambda values
143 (**Supplementary Figure 1**) indicated no evidence of inflation. We identified 298
144 SNPs for AVB, 10 for LBBB, and 1 for RBBB reached GW-significance (i.e.,
145 $\text{p-value} < 5 \times 10^{-8}$). After LD clumping, 10 SNPs remained for AVB (2 novel
146 SNPs), 4 SNPs for LBBB (2 novel SNPs), and none for RBBB. Details of clumped
147 SNPs are listed in **Table 1**. We identified 10 loci for AVB and 4 loci for LBBB,
148 respectively, in which 2 novel loci for both AVB (rs56065557, rs7433306) and LBBB
149 (rs1472095, rs9636578) were identified.

150 We then mapped potential genes according to distances on each chromosome for
151 indexed SNPs. We identified *PLEKHA3*, *TTN*, *FNDC3B*, *SEN2*, *SCN10A*, *RRH*,
152 *PPARGC1A*, *PKD2L2*, *NKX2-5*, *TBX20* as potential genes for AVB indexed SNPs.
153 For LBBB indexed SNPs, the potential genes included *PPARGC1A*, *HAND1*, *TBX5*,
154 and *ADAMTS5*.

155 **TWAS analysis indicated *SCN10A* as potential modulator for AVB**

156 In the single-tissue internal validation using FUSION, of the 5,886 genes
157 included in our genotype data showing significant cis-genetic expression in whole
158 blood according to the GTEx dataset, 10 and 2 genes revealed significant association
159 signals in the TWAS with a FDR p-value less than 0.05 for AVB and LBBB,
160 respectively, as detailed in **Supplementary Table S2** and illustrated in
161 **Supplementary Figure 2**. No significant results were obtained for RBBB GWAS.
162 After colocalization analysis, there were only 4 genes with $\text{PP.H4} > 0.80$. In
163 subsequent joint/conditional tests, we found that after conditioning on
164 ENSG00000185313.6 (*SCN10A*) in the AVB GWAS data on chromosome 3, in which
165 this locus goes from being genome-wide significant to non-significant after
166 conditioning on the predicted expression of ENSG00000185313.6 (*SCN10A*), as
167 shown in **Supplementary Figure 3**. The other 3 genes didn't have any locus with
168 strong enough signals to visualize due to weak effects or low statistical power.

169 **Genetic correlation estimates showed associations between CCDs with** 170 **cardiovascular traits**

171 Estimates of the genetic correlation between AVB, LBBB, RBBB and 9 risk

172 factors are reported in **Table 2**, in which only results with p-value < 0.0019 are listed.
173 We found that CAD and AF were closely correlated with all 3 CCDs, and HF was
174 correlated with AVB and LBBB. **Supplementary Figure 4** showed genetic
175 associations of clumped locus s against 9 cardiovascular traits. Notably, while AVB
176 and PR interval exhibited a strong correlation, we did not identify a significant
177 correlation between QRS duration and LBBB/RBBB. This is likely due to the fact that
178 PR interval and AVB are both focused on the atrioventricular node, a specific
179 conduction pathway, whereas QRS duration reflects a broader range of electrical
180 processes within the ventricles. These processes may not always align genetically
181 with the more localized conduction abnormalities in LBBB and RBBB. The
182 difference in complexity and specificity of these traits explains why a strong genetic
183 correlation was found in the former pair but not in the latter. Additionally, we found
184 that BrS and RBBB didn't share as much strong genetic correlation as expected. This
185 might indicate that although initially reported as a RBBB-like ECG change²⁷, BrS and
186 RBBB are distinct diseases with different genetic background.

187 **ECG-wide associations**

188 The influence of indexed SNPs on ECG morphology is shown in
189 **Supplementary Figure 5**. We showed the ECG morphology phenotype plots as well
190 as the heatmaps for the indexed SNPs. The plots showed that the genetic ECG signature of
191 AVB clumped SNPs mainly affected the PR-segment morphology on the ECG, and LBBB
192 indexed SNPs mainly affected the QRS wave morphology.

193 **PheWAS analysis**

194 The results of PheWAS were present in **Supplementary Table 5**. We found that
195 apart from AF and some common ECG traits such as PR interval, HR, the indexed
196 SNPs in our analysis were also to be highly associated with other non-cardiac traits,
197 such as estimated glomerular filtration rate, impedance measures, body
198 anthropometric traits, etc. Because the GWAS data of ECG traits from Genevieve
199 Wojcik et al²⁸ were not from individuals of European ancestry, we excluded those
200 from our results and conducted colocalization analysis. After colocalization analysis,
201 we identified that some traits with high colocalization evidence (PP.H4 > 0.80) with
202 indexed SNPs, and the virtualization of those results were present in **Supplementary**
203 **Figure 6 - 11**.

204 **Discussion**

205 In this meta-analysis of GWAS for 3 clinically important CCDs using 2
206 independent cohorts, we identified 10 and 2 genome-wide disease susceptibility loci
207 for AVB and LBBB, respectively, including 2 novel locus were identified for each
208 GWAS. Our findings primarily highlighted genes involved in ion channel function,
209 sarcomere function, cardiac development and energy modulation, supporting and
210 extending previous findings suggesting an genetic basis of CCDs and underscore the
211 complex genetic architecture underlying these disorders³⁻⁶. Additionally, they suggest
212 potential pathways for future research and therapeutic targeting.

213 Most susceptibility locus are associated with genes that affect cardiac ion
214 channels, such as *SCN10A*, *TBX20* and *TBX5*. Variations in *SCN10A* have been
215 identified to influence cardiac conduction and PR interval²⁹. TWAS analysis also

216 suggested *SCN10A* as an important regulator for AVB. The T-box proteins are also
217 essential for cardiac conduction system morphogenesis and activation or repression of
218 key regulatory genes³⁰. These genes primarily impact the cardiac conduction system,
219 potentially leading to conduction delays.

220 We also observed susceptibility locus for both AVB and LBBB that mapped to
221 *PPARGCIA* (also known as *PGC-1 α*), an important mitochondrial energy metabolism
222 factor, suggesting that *PPARGCIA* may be an important modulator for cardiac
223 conduction. *PPARGCIA* is involved in the regulation of oxidative phosphorylation
224 and mitochondrial biogenesis, processes critical for maintaining cellular energy
225 homeostasis, and is closely associated with cardiovascular diseases³¹. Disruption of
226 mitochondrial function can lead to altered ion channel expression and disrupted Ca²⁺
227 homeostasis, which in turn increases susceptibility to arrhythmias in both atrial³² and
228 ventricular tissues³³ in mice with *PPARGCIA* deficiency.

229 Our results further implicate the cardiac sarcomere for AVB and LBBB. We
230 identified a susceptibility locus for AVB at *PLEKHA3*, located just downstream of
231 *TTN*. *TTN* encodes the large cardiac structural protein titin, which is essential for the
232 assembly and function of vertebrate striated muscles. By providing connections at the
233 level of individual microfilaments, titin helps maintain the delicate balance of forces
234 between the two halves of the sarcomere. Variants in *TTN* are among the most
235 common inheritable risk factors for dilated cardiomyopathy³⁴ and have been
236 associated with early-onset AF³⁵. A recent research also identified *TTN* as an
237 important susceptibility locus for paroxysmal supraventricular arrhythmia related to
238 accessory pathways³⁶.

239 We also found some genes associated with cardiac development. The Small
240 Ubiquitin-like Modifier (SUMO) modification, implicated in various cellular
241 processes including protein trafficking, transcriptional regulation, protein stability,
242 cell death, and survival, is important to maintain physiological function.
243 SUMOylation of several ion channels such as *SCN5A* to affect conduction³⁷. We
244 found *SENP2*, a key member of the *SENPs* family that regulates SUMOylation, in
245 AVB susceptibility locus. The downstream target of *SENP2* including *NKX2-5*³⁸,
246 another identified gene in AVB GWAS data, which functions in heart formation and
247 development. Mutations in this gene cause atrial septal defect with atrioventricular
248 conduction defect, and also tetralogy of Fallot, which are both heart malformation
249 diseases³⁹. Another gene with potential influence on cardiac development is *HAND1*
250 as one of LBBB susceptibility locus. *HAND1* is a key transcription factor involved in
251 early cardiogenesis. It is one of two closely related family members known as the
252 *HAND* proteins, which are asymmetrically expressed in the developing ventricular
253 chambers and play an essential role in cardiac morphogenesis. Acting in a
254 complementary manner, these proteins are crucial for the formation of the right
255 ventricle and the aortic arch arteries, implicating them as significant mediators of
256 congenital heart disease⁴⁰.

257 We also observed some genes, such as *RRH*, *FNDC3B*, and *ADAMTS5*, that
258 have not been extensively studied in the context of cardiovascular function.
259 Additionally, our PheWAS analysis revealed that some indexed SNPs were closely

260 associated with non-cardiac traits, including estimated glomerular filtration rate
261 (eGFR). These findings suggest a broader role for these genes and SNPs beyond
262 traditional cardiovascular implications, highlighting the need for further investigation
263 into their functions.

264 **Limitations**

265 We recognize several limitations in our analysis. Firstly, the genetic data
266 primarily derives from individuals of European ancestry, which may restrict the
267 applicability of our findings to other ethnic groups. Secondly, despite a total sample
268 size exceeding 700,000, we did not retain SNPs in the RBBB GWAS data after
269 clumping. Further studies are necessary to address this gap.

270 **Conclusion**

271 In this meta-analysis of GWAS including 2 independent cohorts and over
272 700,000 European individuals, we identified 10 and 2 previously reported
273 genome-wide associations with AVB and LBBB, respectively, and 2 novel
274 associations for each GWAS. Our findings primarily implicate genes involved in ion
275 channel function, cardiac development, sarcomere function and energy modulation as
276 important potential effectors of risk for AVB and LBBB.

277 **Data availability**

278 All the data used were acquired from publicly available dataset according to the
279 PubMed ID or links provided in **Stable 1**. No restricted dataset was used in this study.
280 The summary statistics didn't contain any personal information. For code supporting
281 this manuscript, please refer to <https://github.com/bingxunli/block>.

282 **Authors' contributions**

283 BX Li and HX Xu (first author): Conceptualization, Methodology, Software,
284 Investigation, Formal Analysis, Writing and Original Draft; Y Chen and YY Lin: Data
285 Curation, Writing and Original Draft; L Wu (Corresponding Author): Writing, Review
286 and Editing, Funding acquisition. All authors have reviewed the manuscript and
287 approved its submission in current version.

288 **Ethics approval**

289 Not applicable

290 **Consent to participate**

291 Not applicable

292 **Consent for publication**

293 Not applicable

294 **Acknowledgments**

295 We would like to extend our deepest appreciation to the providers of open data
296 and all the individuals who participated in the studies.

297 **Funding**

298 This work is funded by National Natural Science Foundation of China (Project
299 approval number: 82370312).

300 **References**

301 1 Kusumoto, F. M. *et al.* 2018 ACC/AHA/HRS Guideline on the Evaluation and

- 302 Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of
303 the American College of Cardiology/American Heart Association Task Force on
304 Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation* **140**,
305 e382-e482, doi:10.1161/cir.0000000000000628 (2019).
- 306 2 Li, T., Marashly, Q., Kim, J. A., Li, N. & Chelu, M. G. Cardiac conduction diseases:
307 understanding the molecular mechanisms to uncover targets for future treatments.
308 *Expert opinion on therapeutic targets* **28**, 385-400,
309 doi:10.1080/14728222.2024.2351501 (2024).
- 310 3 Kaess, B. M. *et al.* Familial Clustering of Cardiac Conduction Defects and Pacemaker
311 Insertion. *Circulation. Arrhythmia and electrophysiology* **12**, e007150,
312 doi:10.1161/circep.119.007150 (2019).
- 313 4 Dyssekilde, J. R. *et al.* Familial risk of atrioventricular block in first-degree relatives.
314 *Heart* **108**, 1194-1199, doi:10.1136/heartjnl-2021-320411 %J Heart (2022).
- 315 5 Resdal Dyssekilde, J. *et al.* Diagnostic Yield of Genetic Testing in Young Patients With
316 Atrioventricular Block of Unknown Cause. *Journal of the American Heart Association*
317 **11**, e025643, doi:10.1161/jaha.121.025643 (2022).
- 318 6 Thorolfsdottir, R. B. *et al.* Genetic insight into sick sinus syndrome. *European heart*
319 *journal* **42**, 1959-1971, doi:10.1093/eurheartj/ehaa1108 (2021).
- 320 7 Little, J. *et al.* STrengthening the REporting of Genetic Association Studies (STREGA):
321 an extension of the STROBE statement. *PLoS medicine* **6**, e22,
322 doi:10.1371/journal.pmed.1000022 (2009).
- 323 8 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

- 324 *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 325 9 Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
326 population. *Nature* **613**, 508-518, doi:10.1038/s41586-022-05473-8 (2023).
- 327 10 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
328 genomewide association scans. *Bioinformatics (Oxford, England)* **26**, 2190-2191,
329 doi:10.1093/bioinformatics/btq340 (2010).
- 330 11 Rasooly, D. *et al.* Genome-wide association analysis and Mendelian randomization
331 proteomics identify drug targets for heart failure. *Nature communications* **14**, 3826,
332 doi:10.1038/s41467-023-39253-3 (2023).
- 333 12 Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts
334 complex trait gene targets. *Nature genetics* **48**, 481-487, doi:10.1038/ng.3538 (2016).
- 335 13 Schubach, M., Maass, T., Nazaretyan, L., Röner, S. & Kircher, M. CADD v1.7: using
336 protein language models, regulatory CNNs and other nucleotide-level scores to
337 improve genome-wide variant predictions. *Nucleic acids research* **52**, D1143-d1154,
338 doi:10.1093/nar/gkad989 (2024).
- 339 14 Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association
340 studies. *Nature genetics* **48**, 245-252, doi:10.1038/ng.3506 (2016).
- 341 15 The GTEx Consortium atlas of genetic regulatory effects across human tissues.
342 *Science (New York, N.Y.)* **369**, 1318-1330, doi:10.1126/science.aaz1776 (2020).
- 343 16 Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
344 association studies using summary statistics. *PLoS genetics* **10**, e1004383,
345 doi:10.1371/journal.pgen.1004383 (2014).

- 346 17 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
347 polygenicity in genome-wide association studies. *Nature genetics* **47**, 291-295,
348 doi:10.1038/ng.3211 (2015).
- 349 18 Barc, J. *et al.* Genome-wide association analyses identify new Brugada syndrome risk
350 loci and highlight a new mechanism of sodium channel regulation in disease
351 susceptibility. *Nature genetics* **54**, 232-239, doi:10.1038/s41588-021-01007-6 (2022).
- 352 19 Shah, S. *et al.* Genome-wide association and Mendelian randomisation analysis
353 provide insights into the pathogenesis of heart failure. *Nature communications* **11**, 163,
354 doi:10.1038/s41467-019-13690-5 (2020).
- 355 20 Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and
356 genes for coronary artery disease in over a million participants. *Nature genetics* **54**,
357 1803-1815, doi:10.1038/s41588-022-01233-6 (2022).
- 358 21 Nielsen, J. B. *et al.* Biobank-driven genomic discovery yields new insight into atrial
359 fibrillation biology. *Nature genetics* **50**, 1234-1239, doi:10.1038/s41588-018-0171-3
360 (2018).
- 361 22 Ntalla, I. *et al.* Multi-ancestry GWAS of the electrocardiographic PR interval identifies
362 202 loci underlying cardiac conduction. *Nature communications* **11**, 2542,
363 doi:10.1038/s41467-020-15706-x (2020).
- 364 23 Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci
365 associated with blood pressure traits. *Nature genetics* **50**, 1412-1425,
366 doi:10.1038/s41588-018-0205-x (2018).
- 367 24 van de Vegte, Y. J. *et al.* Genetic insights into resting heart rate and its role in

- 368 cardiovascular disease. *Nature communications* **14**, 4646,
369 doi:10.1038/s41467-023-39521-2 (2023).
- 370 25 Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in
371 complex traits. *Nature genetics* **51**, 1339-1348, doi:10.1038/s41588-019-0481-0
372 (2019).
- 373 26 Verweij, N. *et al.* The Genetic Makeup of the Electrocardiogram. *Cell Syst* **11**,
374 229-238.e225, doi:10.1016/j.cels.2020.08.005 (2020).
- 375 27 Brugada, J., Brugada, R. & Brugada, P. Right bundle-branch block and ST-segment
376 elevation in leads V1 through V3: a marker for sudden death in patients without
377 demonstrable structural heart disease. *Circulation* **97**, 457-460,
378 doi:10.1161/01.cir.97.5.457 (1998).
- 379 28 Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for
380 complex traits. *Nature* **570**, 514-518, doi:10.1038/s41586-019-1310-4 (2019).
- 381 29 Chambers, J. C. *et al.* Genetic variation in SCN10A influences cardiac conduction.
382 *Nature genetics* **42**, 149-152, doi:10.1038/ng.516 (2010).
- 383 30 van Eif, V. W. W., Devalla, H. D., Boink, G. J. J. & Christoffels, V. M. Transcriptional
384 regulation of the cardiac conduction system. *Nature reviews. Cardiology* **15**, 617-630,
385 doi:10.1038/s41569-018-0031-y (2018).
- 386 31 Qian, L. *et al.* Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1)
387 family in physiological and pathophysiological process and diseases. *Signal*
388 *transduction and targeted therapy* **9**, 50, doi:10.1038/s41392-024-01756-w (2024).
- 389 32 Chadda, K. R. *et al.* Gene and Protein Expression Profile of Selected Molecular

- 390 Targets Mediating Electrophysiological Function in Pgc-1 α Deficient Murine Atria.
391 *International journal of molecular sciences* **19**, doi:10.3390/ijms19113450 (2018).
- 392 33 Saadeh, K. *et al.* Molecular basis of ventricular arrhythmogenicity in a Pgc-1 α deficient
393 murine model. *Molecular genetics and metabolism reports* **27**, 100753,
394 doi:10.1016/j.ymgmr.2021.100753 (2021).
- 395 34 Herman, D. S. *et al.* Truncations of titin causing dilated cardiomyopathy. *The New*
396 *England journal of medicine* **366**, 619-628, doi:10.1056/NEJMoa1110186 (2012).
- 397 35 Choi, S. H. *et al.* Association Between Titin Loss-of-Function Variants and Early-Onset
398 Atrial Fibrillation. *Jama* **320**, 2354-2364, doi:10.1001/jama.2018.18179 (2018).
- 399 36 Weng, L. C. *et al.* Meta-Analysis of Genome-Wide Association Studies Reveals
400 Genetic Mechanisms of Supraventricular Arrhythmias. *Circulation. Genomic and*
401 *precision medicine* **17**, e004320, doi:10.1161/circgen.123.004320 (2024).
- 402 37 Yoon, J. Y. *et al.* SUMOylation of the cardiac sodium channel Na(V)1.5 modifies
403 inward current and cardiac excitability. *Heart rhythm* **20**, 1548-1557,
404 doi:10.1016/j.hrthm.2023.07.067 (2023).
- 405 38 Wang, J., Zhang, H., Iyer, D., Feng, X. H. & Schwartz, R. J. Regulation of cardiac
406 specific nkx2.5 gene activity by small ubiquitin-like modifier. *The Journal of biological*
407 *chemistry* **283**, 23235-23243, doi:10.1074/jbc.M709748200 (2008).
- 408 39 Cao, C. *et al.* Nkx2.5: a crucial regulator of cardiac development, regeneration and
409 diseases. *Frontiers in cardiovascular medicine* **10**, 1270951,
410 doi:10.3389/fcvm.2023.1270951 (2023).
- 411 40 Riley, P., Anson-Cartwright, L. & Cross, J. C. The Hand1 bHLH transcription factor is

412 essential for placentation and cardiac morphogenesis. *Nature genetics* **18**, 271-275,

413 doi:10.1038/ng0398-271 (1998).

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446 Figure 1 Schematic diagram.

447 AVB, atrioventricular block; LBBB, left bundle branch block; RBBB, bundle branch

448 block; SNP, Single-Nucleotide Polymorphism; LD, linkage disequilibrium; LDSC,

449 LD score regression; PheWAS, phenome-wide association study; TWAS,

450 transcriptome-wide association study

451

452 Figure 2. Manhattan plots showing GWAS meta-analysis of. A) AVB; B) LBBB; and

453 C) RBBB. Those plots shows the $-\log_{10}(\text{p-value})$ of association for each SNP from

454 the GWAS meta-analysis plotted on the y-axis against genomic position on the x-axis.
455 The gray line corresponds to the genome-wide significance threshold (5×10^{-8}).
456 Novel locus identified genes are highlighted in bold.
457

SNP	CHR	POS	EA	NEA	EAF	N	BETA	SE	p-value	nearest gene	CADD scaled score
AVB											
rs185591978	2	178488129	A	G	0.94	349625	-0.03	0.005	2.60×10^{-9}	<i>PLEKHA3</i>	1.44
rs13031826	2	178891875	A	T	0.88	732669	-0.02	0.003	1.19×10^{-12}	<i>TTN</i>	4.28
rs10936712	3	172084486	T	C	0.69	349625	-0.01	0.003	1.48×10^{-8}	<i>FNDC3B</i>	3.09
rs56065557	3	185636428	C	G	0.70	732669	-0.01	0.002	8.35×10^{-9}	<i>SEN2</i>	1.44
rs7433306	3	38729148	C	G	0.57	732669	0.01	0.002	1.45×10^{-10}	<i>SCN10A</i>	0.29
rs199561133	4	110760807	T	G	0.86	349625	-0.02	0.003	2.59×10^{-8}	<i>RRH</i>	0.57
rs2932971	4	23817261	T	C	0.71	732669	0.01	0.002	1.89×10^{-10}	<i>PPARGCIA</i>	19.3
rs76734697	5	137897780	T	G	0.81	732669	0.01	0.002	2.73×10^{-9}	<i>PKD2L2</i>	3.15
rs6556061	5	173218944	A	T	0.72	349625	-0.02	0.003	2.62×10^{-9}	<i>NKX2-5</i>	0.11
rs11764098	7	35466100	C	G	0.97	732669	-0.04	0.005	2.52×10^{-13}	<i>TBX20</i>	18.1
LBBB											
rs1472095	4	23816454	T	C	0.71	727785	0.010	0.002	3.35×10^{-8}	<i>PPARGCIA</i>	3.29
rs13185595	5	154492610	A	G	0.63	727785	-0.012	0.002	5.55×10^{-13}	<i>HAND1</i>	7.93
rs61931006	12	114414703	A	C	0.90	727785	0.018	0.003	4.10×10^{-11}	<i>TBX5</i>	2.64
rs9636578	21	27538384	A	G	0.52	727785	-0.001	0.002	4.02×10^{-8}	<i>ADAMTS5</i>	2.94

458 Table 1. Locus reported for AVB and LBBB in the meta-analysis of UK Biobank and FinnGene GWAS datasets. Findings were identified using
 459 fixed effects inverse-variance weighted meta-analysis. The chromosomal position is based on GRCh37/hg19 reference. Gene names are
 460 italicized. Novel locus (i.e., distance > 500kB from previous locus) are shown in bold. CHR, chromosome; POS, base pair location; NEA,
 461 non-effect allele; EA, effect allele; EAF, effect allele frequency; SE, standard error; CADD, Combined Annotation Dependent Depletion

462

Trait1	Trait2	r_g	SE	p-value
AVB	AF	0.46	0.07	6.86×10^{-10}
	CAD	0.30	0.05	1.18×10^{-9}
	HF	0.48	0.08	5.17×10^{-10}
	SSS	0.32	0.07	5.85×10^{-6}
	PR	0.76	0.17	5.41×10^{-6}
	HR	0.19	0.04	1.98×10^{-5}
LBBB	AF	0.26	0.07	1.19×10^{-4}
	CAD	0.40	0.06	7.59×10^{-12}
	HF	0.65	0.10	2.83×10^{-10}
	SBP	0.24	0.05	7.16×10^{-6}
RBBB	AF	0.36	0.11	1.10×10^{-3}
	CAD	0.51	0.09	2.50×10^{-8}

463 Table 2. LDSC analysis results showing genetic correlations between CCDs and
464 related cardiovascular traits. Here only significant results were present. AVB,
465 atrioventricular block; LBBB, left bundle branch block; RBBB, right bundle branch
466 block; AF, atrial fibrillation; CAD, coronary heart disease; HF, heart failure; SSS, sick
467 sinus syndrome; SBP, systolic blood pressure; r_g , genetic correlation; SE, standard
468 error.



